Home » Stocks » SPRO

Spero Therapeutics, Inc. (SPRO)

Stock Price: $12.39 USD -1.03 (-7.68%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Market Cap 391.52M
Revenue (ttm) 14.93M
Net Income (ttm) -74.45M
Shares Out 29.41M
EPS (ttm) -3.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $12.39
Previous Close $13.42
Change ($) -1.03
Change (%) -7.68%
Day's Open 13.42
Day's Range 12.36 - 13.42
Day's Volume 154,149
52-Week Range 8.50 - 23.64

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializin...

1 month ago - GlobeNewsWire

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 11.69% and -41.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st...

1 month ago - Zacks Investment Research

Tebipenem HBr advancing towards NDA submission in the second half of 2021

1 month ago - GlobeNewsWire

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializin...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

3 months ago - GlobeNewsWire

Spero Therapeutics (SPRO) has been struggling lately, but the selling pressure may be coming to an end soon.

3 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

3 months ago - GlobeNewsWire

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for high unmet need areas involving multi-drug-resistant bacterial infections and rare diseases. Spero is run...

3 months ago - Seeking Alpha

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

5 months ago - GlobeNewsWire

Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...

6 months ago - GlobeNewsWire

Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise in ...

Other stocks mentioned: BPMC, ANAB, DRNA, QURE
6 months ago - Insider Monkey

15 data presentations cover each of Spero's three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial 15 data presentations cover each of Spero's three ...

6 months ago - GlobeNewsWire

Spero Therapeutics (SPRO) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ...

7 months ago - GlobeNewsWire

The pricing of a stock offering is causing the drugmaker's shares to fall.

7 months ago - The Motley Fool

CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ...

8 months ago - GlobeNewsWire

Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and...

8 months ago - GlobeNewsWire

The FDA accepts Spero's (SPRO) IND for SPR720 in development for the treatment of nontuberculous mycobacterial pulmonary disease.

8 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializin...

8 months ago - GlobeNewsWire

Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 27.35% and -41.46%, respectively, for the quarter ended June 2020.

9 months ago - Zacks Investment Research

Top-line data for Phase 3 ADAPT-PO trial evaluating oral tebipenem HBr in complicated urinary tract infection expected in 3Q20  

9 months ago - GlobeNewsWire

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

9 months ago - Zacks Investment Research

CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...

11 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Spero Therapeutics, Inc. (SPRO).

11 months ago - Zacks Investment Research

Spero Therapeutics, Inc. (SPRO) CEO Dr.

11 months ago - Seeking Alpha

Spero Therapeutics Inc (SPRO) delivered earnings and revenue surprises of 9.63% and -49.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Tebipenem HBr Phase 3 trial enrollment complete with top-line data expected in the third quarter of 2020

1 year ago - GlobeNewsWire

ADAPT-PO topline results expected in the third quarter of 2020 ADAPT-PO topline results expected in the third quarter of 2020

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ...

1 year ago - GlobeNewsWire

Spero brings significant commercial leadership and business development experience to its Board of Directors with appointment of pharmaceutical veteran, Scott Jackson Spero brings significant commercial...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ...

1 year ago - GlobeNewsWire

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -21.10% and 2.46%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

CAMBRIDGE, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...

1 year ago - GlobeNewsWire

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...

1 year ago - GlobeNewsWire

$30 Million fully backstopped rights offering will be available to all stockholders of record on February 10, 2020 $30 Million fully backstopped rights offering will be available to all stockholders of ...

1 year ago - GlobeNewsWire

About SPRO

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment ... [Read more...]

Industry
Biotechnology
IPO Date
Nov 2, 2017
CEO
Ankit Mahadevia
Employees
89
Stock Exchange
NASDAQ
Ticker Symbol
SPRO
Full Company Profile

Financial Performance

In 2020, SPRO's revenue was $9.33 million, a decrease of -48.59% compared to the previous year's $18.15 million. Losses were -$78.28 million, 28.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for SPRO stock is "Strong Buy." The 12-month stock price forecast is 33.00, which is an increase of 166.34% from the latest price.

Price Target
$33.00
(166.34% upside)
Analyst Consensus: Strong Buy